GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Homology Medicines Inc (STU:35H) » Definitions » Institutional Ownership

Homology Medicines (STU:35H) Institutional Ownership : 0.38% (As of Jun. 01, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Homology Medicines Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Homology Medicines's institutional ownership is 0.38%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Homology Medicines's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Homology Medicines's Float Percentage Of Total Shares Outstanding is 89.53%.


Homology Medicines Institutional Ownership Historical Data

The historical data trend for Homology Medicines's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Homology Medicines Institutional Ownership Chart

Homology Medicines Historical Data

The historical data trend for Homology Medicines can be seen below:

2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29
Institutional Ownership 0.56 0.59 0.59 0.58 0.57 7.74 7.71 7.19 6.86 0.38

Homology Medicines Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Homology Medicines (STU:35H) Business Description

Traded in Other Exchanges
Address
One Patriots Park, Bedford, MA, USA, 01730
Homology Medicines Inc is a United States-based genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.

Homology Medicines (STU:35H) Headlines

No Headlines